Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Dennis Dietrich

Neurology Great Falls, MT Medical Doctor

NPI 1871677245 CMS profile 786807

400 15Th Ave S, Ste 206, Great Falls, MT 59405

Open in the dashboard

General payments

$140,260

383 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$565,582 paid to institutions, not to them · program years 2019–2024

Through program year 2022, Dennis Dietrich of Great Falls, MT is reported in the CMS Open Payments database as having received $140,260 across 383 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $565,582 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $31,763 37
2021 General $33,589 87
2020 General $28,220 116
2019 General $46,687 143

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dennis Dietrich
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Dennis Dietrich were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Dennis Dietrich Neurology median Middle half National median
2019 $46,687 $474 $118–$2,177 $163
2020 $28,220 $367 $82–$2,309 $114
2021 $33,589 $438 $104–$2,547 $132
2022 $31,763 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Biogen, Inc. $92,827 180 payments
  2. Genzyme Corporation $37,856 58 payments
  3. Novartis Pharmaceuticals Corporation $7,383 51 payments
  4. Teva Pharmaceuticals USA, Inc. $397 25 payments
  5. Celgene Corporation $384 3 payments
  6. Genentech USA, Inc. $268 15 payments
  7. Sentynl Therapeutics, Inc. $219 1 payment
  8. Amgen Inc. $210 9 payments
  9. Neurocrine Biosciences, Inc. $144 7 payments
  10. Sarepta Therapeutics, Inc. $105 5 payments
  11. Other $467 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $99,468 38 payments
  2. Consulting Fee $25,714 11 payments
  3. Travel and Lodging $9,026 49 payments
  4. Food and Beverage $5,943 283 payments
  5. Education $109 2 payments
Products named General payments · program years 2019–2022
  1. VUMERITY $38,839 67 payments
  2. TYSABRI $35,111 86 payments
  3. AUBAGIO Multiple Sclerosis $19,109 25 payments
  4. TECFIDERA $16,356 46 payments
  5. AUBAGIO Neurology $5,912 17 payments
  6. MAYZENT $3,234 24 payments
  7. AVONEX $2,056 2 payments
  8. PLEGRIDY $2,048 1 payment
  9. KESIMPTA $1,270 14 payments
  10. GILENYA $346 18 payments
  11. Other $1,902 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

383 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record